Roche pays €380M for NLRP3 biotech Inflazome, claiming a leading position in hot field Bischofberger's Kronos files for IPO to run pivotal cancer trial ESMO: Amgen's KRAS drug tackles 32% of lung cancers—and this is just the beginning Flagship Pioneering's 2-becomes-one biotech nabs ex-Pfizer CSO as research lead ESMO: Early days, but Amgen's BiTE drug in prostate cancer shows encouraging activity Bausch inks $50M option to grab Allegro's eye disease pipeline ESMO: Adding Elevar's EGFR drug to AstraZeneca's Iressa boosts survival in early lung cancer Boosting immuno-oncology drugs by recruiting immune messenger cells Illumina to pay $8B to reacquire cancer blood test maker Grail, with all eyes on 2021 Featured Story | By Nick Paul Taylor Roche has bought Inflazome for €380 million ($451 million) upfront to gain control of treatments for inflammatory diseases. The deal gives Roche full rights to a pipeline of oral NLRP3 inhibitors led by two clinical-phase drugs Inflazome is developing as treatments for Parkinson’s and other diseases. read more |
| |
|---|
|
| | In our recent 90 Second Insight video, WCG ThreeWire's Molly Hair, Director of Site Engagement and Management, discusses how study staffing shortages due to COVID-19 are affecting clinical research in oncology. Visit wcgclinical.com to see how our Site Support and Augmentation Services can get your oncology trial back on track. |
Top Stories By Nick Paul Taylor Norbert Bischofberger’s Kronos Bio has filed to raise up to $100 million in a Nasdaq IPO. The IPO haul will set Kronos up to start a registrational phase 2/3 trial of a first-line acute myeloid leukemia drug licensed from Bischofberger's former employer Gilead. read more By Amirah Al Idrus After releasing dribs and drabs about its closely watched KRAS inhibitor, Amgen is pulling the curtain on full data. The treatment, known as sotorasib or AMG 510, curbed tumor growth in 88% of patients with non-small cell lung cancer, shrinking tumors in one-third of patients. read more By Ben Adams The former CEO and founder of Pandion Therapeutics and ex-chief scientific officer of Pfizer Anthony Coyle, Ph.D., has signed up to run Repertoire Immune Medicines’ R&D. read more By Ben Adams Amgen’s test for advanced prostate cancers has shown encouraging signs in an early trial, and it hopes to move past the limited efficacy seen in other immune therapies for the disease. read more By Amirah Al Idrus Leaning into its new name, Bausch Health is laying the groundwork for a pipeline expansion. It’s forking over $10 million upfront for the option to acquire Allegro Ophthalmics’ eye disease assets, including its retinal disease med risuteganib. If Allegro pulls off another financing, Bausch will hand over the remaining $40 million, likely in 2021. read more By Ben Adams AstraZeneca's Tagrisso has taken firm hold of the EGFR market over the last few years, pushing aside drugs including AZ's own older drug Iressa. But could a combo approach be a viable alternative? read more By Angus Liu Scientists at University Hospital Zurich showed that immune signaling molecule IL-2 might provide vital support to immuno-oncology agents by engaging with dendritic cells, which function as the messengers of the immune system by presenting antigens to T cells. read more By Conor Hale Illumina will put down a total of $8 billion to reacquire its former spinout Grail, which, after nearly five years on its own, is nearing completion of a simple blood test capable of detecting 50 different cancers in their earliest stages. read more Resources Sponsored by: Evidation Health Achieving patient centricity depends on evolving how evidence is generated. Sponsored by: Outer Edge Technology Cybercriminals Are Actively Exploiting The Coronavirus Pandemic To Gain Entry To Enterprise Networks. Don’t Let Your Company Become The Next Ransomware Headline -- Make These Changes Now! Sponsored by: 4G Clinical This white paper addresses the complexity of basket and umbrella designs, and how modern technology is critical to run flexible, agile and quality-driven trials. Sponsored by: EVERSANA How independent drug launch and commercialization can lead to higher market capitalization. Sponsored by: AMRI Download our white paper to learn more about the growth trends, complex anatomy and intricacies of developing these armed antibodies, as well as AMRI’s approach to their discovery and development. Sponsored by: LexisNexis Risk Solutions Avoid severe compliance penalties by staying on top of evolving laws. Sponsored by: Quotient Sciences This white paper will discuss four principal CMC challenges for the developers of orphan drugs, and the potential solutions which are emerging. Download now >> Sponsored by: Clarify Health In 2020, QED Therapeutics launched first-in-class infigratinib for cholangiocarcinoma (CCA). Learn how the launch team precisely identified and characterized eligible patients by taking an evidence-based approach to its commercial strategy. Sponsored by: Benchling Life science R&D generates a LOT of data. Learn how to make sense of it and harness its potential with this step-by-step guide. Sponsored by: Thermo Fisher Scientific Don’t oversimplify your solubility challenges. Sponsored by: Clinical Ink Download this free whitepaper to learn how to execute fast, high-quality clinical trials through eSource for studies that boost efficiency for both sponsors and sites. Sponsored by: PRA Health Sciences Drug developers and stakeholders must find ways to collaborate, rather than compete, as the RACE Act prompts the need for more pediatric research. Sponsored by: Catalent Get insights on key considerations for a successful tech transfer process for manufacturing a biologic drug product, including a case study on overcoming challenges in a process transfer for a sterile diluent. Sponsored by: Thermo Fisher Scientific Download the whitepaper to learn more. Sponsored by: LexisNexis Risk Solutions Traditionally, pharma companies use a combination of prescription data & internal sales reports to look for potential buyers. Such practice provides only a LIMITED VIEW without competitor information. Download the whitepaper by Optum to see how novel data platforms can uncover hidden insights on medication adherence helping life sciences companies maximize product utilization. Sponsored by: Catalent Pharmaceutical and biotech companies are spending years developing drugs or promising new biologics, all with the hopes of saving or enhancing patients’ lives. It’s a “race to the finish” in some cases, and the quicker a company can get its product to patients, the better. Sponsored by: Paysign Download the whitepaper for a solution designed to connect manufacturers, pharmacists, and patients. In this special guide, you will learn not just about the law but about the portal platform designed to change the entire process for all. Sponsored by: Cardinal Health 3PL Services Identifying opportunities to simplify channel strategies and business processes for biopharma companies, their customers and patients. Sponsored by: Catalent In a BioPharma Dive industry survey, planning and forecasting were identified as top concerns for trial sponsors. In response to this need, the CSM team at Catalent has developed a methodology for identifying, evaluating, and proactively managing the inherent risks involved in clinical trial supply chain management. Sponsored by: Catalent Learn about a real-world example of how clinical supply management expertise was applied to overcome inventory challenges for a complex, global study. Sponsored by: Catalent Whether a study is simple or highly complex, forecasting and simulation reports serve as data driven communication tools to help minimize risks and keep the study on track. Learn more about forecasting solutions for informed decision making and supporting contingency planning for clinical study. Sponsored by: Catalent Learn how to drive excellence within the forecasting process and utilize forecasting throughout the clinical study to better plan clinical supply budgets and project timelines. Explore how to identify potential supply-related issues before they can negatively impact your study. Medtech Innovation Week October 19-22 Drug Development Immersion: Live, Online Course October 21-22, 2020 | 9am - 3:30pm ET Become Fluent In Drug Development With Our Industry Expert October 21-22, 2020 | 9am - 3:30pm ET BioBasics 101: The Biology of Biotech for the Non-Scientist: Live, Online Course November 12-13, 2020 | 9am - 3:30pm ET Drug Development Boot Camp® VIRTUAL 2020 November 18-19, 2020 | Register now! Pre-Boot Camp training ongoing now | Due to COVID19 provisions – training will be conducted VIRTUALLY | Same excellent total immersion training in new medicine development will be made available to experts who want to make a difference to patients. | 